Based on the mechanism of action of this tyrosine kinase inhibitor, the FDA drug label states that vemurafenib is only indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF p.V600E mutation as detected by an FDA-approved test. This evidence concerns the gene BRAF and metastatic melanoma.